ruboxistaurin has been researched along with Cardiac Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD | 1 |
| Wang, LY; Yang, SJ | 1 |
1 review(s) available for ruboxistaurin and Cardiac Hypertrophy
| Article | Year |
|---|---|
[The function of protein kinase C in myocardial fibrosis].
Topics: Animals; Cardiomegaly; Fibrosis; Humans; Indoles; Maleimides; Matrix Metalloproteinase 9; Myocardium; Protein Kinase C; Ventricular Remodeling | 2010 |
1 other study(ies) available for ruboxistaurin and Cardiac Hypertrophy
| Article | Year |
|---|---|
Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Signaling; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Failure; Indoles; Maleimides; Metoprolol; Mice; Mice, Knockout; Myocardial Contraction; Myocardial Infarction; Myocardium; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein Kinase Inhibitors; Pulmonary Edema; Time Factors | 2009 |